A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

Official title:

A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00790218
• Other study ID #: CF102-102HCC
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: February 2009
• Est. completion date: December 2013

Study information

• Verified date: April 2022
• Source: Can-Fite BioPharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis. Treatment will be assessed for adverse effects and for effects on the tumor.

Description:

This is a multicenter, open-label, non-randomized, dose-escalation study, to be conducted in 2 phases: a dose-escalation phase, to determine the MTD of CF102 and to evaluate its safety/tolerability, PK, pharmacodynamic, and preliminary clinical activity; and a dose-confirmation phase, which will be a cohort expansion at or below the MTD (ie, the RP2D) of CF102. Subjects will be treated with oral doses of CF102 in consecutive, 28-day cycles. The initial dose of CF102 will be 1 mg twice daily (BID), with subsequent escalations to 5 and 25 mg BID, unless limited by toxicity. Subjects will be evaluated weekly for the first cycle, every 2 weeks for Cycles 2 and 3, and at the end of each subsequent cycle, up to 6 cycles of CF102 treatment. Subjects will return for a follow-up visit 28 days after completion of the last dose of study drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: December 2013
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of HCC:

• For patients without underlying cirrhosis, diagnosis of HCC documented by cytology and/or histology

• For patients with underlying cirrhosis, diagnosis of HCC established according to the American Association for the Study of Liver Diseases Practice Guideline algorithm (Appendix V).

2. HCC is advanced, refractory, or metastatic, and no standard therapies are expected to be curative.

3. At least 18 years of age.

4. For subjects in the dose-confirmation (RP2D) phase only: Measurable disease, using Response Evaluation Criteria in Solid Tumors (RECIST, Appendix IV). (Note that a lesion that has been subjected to radiotherapy or chemoembolization cannot be used as a target lesion.)

5. Eastern Collaborative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at baseline.

6. The following laboratory values must be documented within 3 days prior to initiation of study drug:

• Absolute neutrophil count (ANC) greater than or equal to 1 x 109/L

• Platelet count greater than or equal to 50 x 109/L

• Serum creatinine less than or equal to 2.0 mg/dL

• Aspartic aminotransferase (AST) and alanine aminotransferase (ALT) = 5 × upper limit of normal.

• Total bilirubin = 3.0 mg/dL.

• Serum albumin = 3.0 g/dL.

• International normalized ratio (INR) = 2.3.

7. Esophageal bleeding and varices, if present, have been sclerosed or banded, and no bleeding episodes have occurred during the prior 6 months.

8. Life expectancy of = 12 weeks.

9. For women of childbearing potential, negative serum pregnancy test result.

10. Absence of active malignancy other than HCC within 2 years of entry, with the exception of basal cell carcinoma and squamous cell carcinoma of the skin.

11. Provide written informed consent to participate.

12. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other study related procedures.

-

Exclusion Criteria:

1. Any chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, corticosteroids > 20 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within 14 days prior to initiation of study drug.

2. Major surgery or radiation therapy within 28 days prior to initiation of study drug.

3. Severe liver dysfunction (Child-Pugh Class C or hepatic encephalopathy).

4. Active infection requiring systemic therapy.

5. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug.

6. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the QTc (Fridericia) interval to > 450 msec for males or > 470 msec for females.

7. Pregnant or lactating female.

8. Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Principal Investigator (PI), are effective and adequate for that patient's circumstances while on study drug.

9. Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (i.e., a condom, with female partner using oral, injectable, or barrier method) while on study drug.

10. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.

11. Any severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the patient inappropriate for entry into this study.

-

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Drug:
• CF102
CF102 capsules twice daily by mouth

Locations

Country	Name	City	State
Israel	Rabin Medical Center	Tel Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Can-Fite BioPharma

Country where clinical trial is conducted

Israel, 

References & Publications (1)

Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle L, Fishman P. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol. 2008 Aug;33(2):287-95. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Limiting Toxicity	Dose-limiting toxicity was defined as a clinically significant AE or laboratory abnormality occurring in Cycle 1	From start of treatment until Day 28 of Cycle 1
Primary	Maximum Tolerated Dose	The MTD was defined as the highest dose level at which < 2 of 6 patients developed Cycle 1 DLT.	first 28 days (Cycle 1)
Primary	Maximum Plasma Concentration of CF102 (Cmax)	Blood samples were collected and plasma concentrations determined using a high-pressure liquid chromatography method.	Dose Escalation Phase on Day 1 and Day 29 pre-dose and at 1, 2, 3, 4, 6, 8 hours post-dose
Secondary	Number of Subjects With Objective Tumor Response	Therapeutic effect of CF102 in hepatocellular carcinoma measured by number of subjects with objective tumor response	6 months
Secondary	Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102	The Peripheral Blood Mononuclear Cells (PBMC) were to be collected at Baseline and Day 28 in order to evaluate the Adenosine A3 receptor (A3AR) and PBMC biomarkers, and clinical effects of CF102.	Baseline to Day 28

External Links

•   Can-Fite BioPharma Ltd